Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2020-N-2197]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 10 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
 DATES: Approval is withdrawn as of January 11, 2021.
 FOR FURTHER INFORMATION CONTACT: Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, 
                        *Martha.Nguyen@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. Application No.
Drug
ApplicantANDA 040323
Prednisolone Syrup, 15 milligrams (mg)/5 milliliters (mL)
VistaPharm, Inc., 7265 Ulmerton Rd., Largo, FL 33771ANDA 075782
Valproic Acid Syrup, 250 mg/5 mL
Do.ANDA 076188
Fosinopril Sodium Tablets, 10 mg, 20 mg, and 40 mg
Upsher-Smith Laboratories, LLC, 6701 Evenstad Dr., Maple Grove, MN 55369ANDA 076189
Mirtazapine Tablets, 15 mg, 30 mg, and 45 mg
Do.ANDA 077537
Glyburide Tablets, 1.25 mg, 2.5 mg, and 5 mg
Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Rd., East Windsor, NJ 08520ANDA 077672
Stavudine Capsules, 15 mg, 20 mg, 30 mg, and 40 mg
Do.ANDA 085055
Tylenol W/Codeine No. 1 (acetaminophen and codeine phosphate) Tablets, 300 mg; 7.5 mg
                             Tylenol W/Codeine No. 2 (acetaminophen and codeine phosphate) Tablets, 300 mg; 15 mg 
                             Tylenol W/Codeine No. 3 (acetaminophen and codeine phosphate) Tablets, 300 mg; 30 mg 
                             Tylenol W/Codeine No. 4 (acetaminophen and codeine phosphate) Tablets, 300 mg; 60 mg
Janssen Pharmaceuticals, Inc., 1000 U.S. Route 202, P.O. Box 300, Raritan NJ 08869ANDA 087266
Lindane Shampoo, 1%
Olta Pharmaceuticals Corp. (an Akorn Company), 1925 West Field Ct., Suite 300, Lake Forest, IL 60045ANDA 087313
Lindane Lotion, 1%
Do.ANDA 089003
Phenytoin Sodium Injection, 50 mg/mL
Fresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047
 Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of January 11, 2021. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on January 11, 2021 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: December 8, 2020. Lauren K. Roth, Acting Principal Associate Commissioner for Policy.


[FR Doc. 2020-27303 Filed 12-10-20; 8:45 am] BILLING CODE 4160-01-P